Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) traded down 5.2% on Friday . The stock traded as low as $3.43 and last traded at $3.44, with a volume of 134,372 shares traded. The stock had previously closed at $3.63.

Several analysts recently weighed in on the company. Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, April 27th. FBR & Co restated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Maxim Group restated a “buy” rating and issued a $6.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, May 17th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, May 18th.

The company’s 50 day moving average is $2.61 and its 200 day moving average is $2.66. The firm’s market cap is $113.80 million.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. Analysts anticipate that Abeona Therapeutics Inc. will post ($0.66) earnings per share for the current year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC increased its stake in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent SEC filing.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.